Form 4: Notable Labs Executive Acquires 200,000 Stock Options

Joseph P. Wagner, Chief Scientific Officer of Notable Labs, Ltd., acquired 200,000 stock options on May 8, 2024, according to a recent SEC filing.

Summary

• On May 8, 2024, Joseph P. Wagner, the Chief Scientific Officer of Notable Labs, Ltd., was granted 200,000 stock options.
• The options have an exercise price of $1.19.
• The options vest in equal monthly installments over a four-year period, subject to an initial one-year cliff.
• The options expire on May 8, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. There are no immediate negative implications.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the vesting schedule are typical for a Chief Scientific Officer role in a company of Notable Labs' size and stage of development.
• Comparable companies in the biotech space often use similar equity-based compensation to attract and retain talent.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the Chief Scientific Officer to work towards increasing shareholder value.

Key Dates

Keywords

Stock Options, Form 4, Notable Labs, Wagner, Executive Compensation, Equity